Dimerix Ltd has surged by 31% as a result of a significant announcement of a partnership with FUSO Pharmaceutical Industries in Japan. This exclusive collaboration focuses on the development and commercialization of DMX-200, a promising drug candidate targeting FSGS, a kidney disease. FUSO will lead the efforts in Japan and provide financial support for the development, regulatory, and commercial initiatives.
Company Information
Company
Dimerix Limited
Location
Melbourne, Victoria, Australia
About
Dimerix is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix' lead candidate is in Phase 3 clinical trials for a rare type of kidney disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.
MelbourneBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma